Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort

被引:6
作者
Forsgren, Mikael F. [1 ,2 ,3 ]
Karlsson, Markus [2 ,3 ]
Leinhard, Olof Dahlqvist [2 ,3 ]
Dahlstrom, Nils [3 ,4 ]
Noren, Bengt [3 ]
Romu, Thobias [3 ,5 ]
Ignatova, Simone [6 ]
Ekstedt, Mattias [7 ]
Kechagias, Stergios [7 ]
Lundberg, Peter [3 ,8 ]
Cedersund, Gunnar [5 ,9 ]
机构
[1] Linkoping Univ, Wolfram MathCore AB, Linkoping, Sweden
[2] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden
[3] Linkoping Univ, Ctr Med Image Sci & Visualizat CMIV, Linkoping, Sweden
[4] Linkoping Univ, Dept Med & Hlth Sci, Dept Radiol Dept, Linkoping, Sweden
[5] Linkoping Univ, Dept Biomed Engn, Linkoping, Sweden
[6] Linkoping Univ, Dept Clin & Expt Med, Dept Clin Pathol & Clin Genet, Linkoping, Sweden
[7] Linkoping Univ, Dept Med & Hlth Sci, Dept Gastroenterol & Hepatol, Linkoping, Sweden
[8] Linkoping Univ, Dept Radiat Phys, Dept Med & Hlth Sci, Linkoping, Sweden
[9] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden
基金
英国医学研究理事会; 瑞典研究理事会;
关键词
GD-EOB-DTPA; ACID-ENHANCED MRI; HEPATOCELLULAR-CARCINOMA; TRANSPORTER EXPRESSION; CONTRAST AGENTS; HEPATIC-UPTAKE; QUANTIFICATION; PERFUSION; ACCURACY; INJURY;
D O I
10.1371/journal.pcbi.1007157
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Estimation of liver function is important to monitor progression of chronic liver disease (CLD). A promising method is magnetic resonance imaging (MRI) combined with gadoxetate, a liver-specific contrast agent. For this method, we have previously developed a model for an average healthy human. Herein, we extended this model, by combining it with a patient-specific non-linear mixed-effects modeling framework. We validated the model by recruiting 100 patients with CLD of varying severity and etiologies. The model explained all MRI data and adequately predicted both timepoints saved for validation and gadoxetate concentrations in both plasma and biopsies. The validated model provides a new and deeper look into how the mechanisms of liver function vary across a wide variety of liver diseases. The basic mechanisms remain the same, but increasing fibrosis reduces uptake and increases excretion of gadoxetate. These mechanisms are shared across many liver functions and can now be estimated from standard clinical images. Author summary Being able to accurately and reliably estimate liver function is important when monitoring the progression of patients with liver disease, as well as when identifying drug-induced liver injury during drug development. A promising method for quantifying liver function is to use magnetic resonance imaging combined with gadoxetate. Gadoxetate is a liver-specific contrast agent, which is taken up by the hepatocytes and excreted into the bile. We have previously developed a mechanistic model for gadoxetate dynamics using averaged data from healthy volunteers. In this work, we extended our model with a non-linear mixed-effects modeling framework to give patient-specific estimates of the gadoxetate transport-rates. We validated the model by recruiting 100 patients with liver disease, covering a range of severity and etiologies. All patients underwent an MRI-examination and provided both blood and liver biopsies. Our validated model provides a new and deeper look into how the mechanisms of liver function varies across a wide variety of liver diseases. The basic mechanisms remain the same, but increasing fibrosis reduces uptake and increases excretion of gadoxetate.
引用
收藏
页数:20
相关论文
共 49 条
[31]   Current concepts - Drug-related hepatotoxicity [J].
Navarro, VJ ;
Senior, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :731-739
[32]   Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: Comparison with Technetium-99m galactosyl serum albumin scintigraphy [J].
Nishie, Akihiro ;
Ushijima, Yasuhiro ;
Tajima, Tsuyoshi ;
Asayama, Yoshiki ;
Ishigami, Kousei ;
Kakihara, Daisuke ;
Nakayama, Tomohiro ;
Takayama, Yukihisa ;
Okamoto, Daisuke ;
Abe, Koichiro ;
Obara, Makoto ;
Yoshimitsu, Kengo ;
Honda, Hiroshi .
EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (06) :1100-1104
[33]   Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes [J].
Nyman, Elin ;
Rozendaal, Yvonne J. W. ;
Helmlinger, Gabriel ;
Hamren, Bengt ;
Kjellsson, Maria C. ;
Stralfors, Peter ;
van Riel, Natal A. W. ;
Gennemark, Peter ;
Cedersund, Gunnar .
INTERFACE FOCUS, 2016, 6 (02)
[34]   ABC protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles [J].
Pascolo, L ;
Petrovic, S ;
Cupelli, F ;
Bruschi, CV ;
Anelli, PL ;
Lorusso, V ;
Visigalli, M ;
Uggeri, F ;
Tiribelli, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (01) :60-66
[35]  
Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO
[36]  
2-S
[37]   Robust water fat separated dual-echo MRI by phase-sensitive reconstruction [J].
Romu, Thobias ;
Dahlstrom, Nils ;
Leinhard, Olof Dahlqvist ;
Borga, Magnus .
MAGNETIC RESONANCE IN MEDICINE, 2017, 78 (03) :1208-1216
[38]   Assessing liver function using dynamic Gd-EOB-DTPA-enhanced MRI with a standard 5-phase imaging protocol [J].
Saito, Kazuhiro ;
Ledsam, Joseph ;
Sourbron, Steven ;
Otaka, Jun ;
Araki, Yoichi ;
Akata, Soichi ;
Tokuuye, Koichi .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2013, 37 (05) :1109-1114
[39]   An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis [J].
Schulze, Jennifer ;
Lenzen, Henrike ;
Hinrichs, Jan B. ;
Ringe, Burckhardt ;
Manns, Michael P. ;
Wacker, Frank ;
Ringe, Kristina I. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (01) :192-+
[40]   Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury-Past, Present, and Future [J].
Senior, J. R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) :332-339